Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

Journal of Experimental Medicine

Volumn 210, Issue 7, 2013, Pages 1389-1402

  Holmgaard, Rikke B ^a   Zamarin, Dmitriy ^a   Munn, David H ^b   Wolchok, Jedd D ^a,c,d   Allison, James P ^a,e  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c Weill Cornell Graduate School of Biomedical Sciences   (United States)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL TRYPTOPHAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG POTENTIATION; EFFECTOR CELL; IMMUNOGENICITY; LYMPHOCYTIC INFILTRATION; MELANOMA; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TUMOR GROWTH; TUMOR REJECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CTLA-4 ANTIGEN; ENZYME INHIBITORS; HUMANS; IMMUNOTHERAPY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; T-LYMPHOCYTE SUBSETS;

EID: 84880664259     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20130066     Document Type: Article

References (74)

1. Attia, P., G.Q. Phan, A.V. Maker, M.R. Robinson, M.M. Quezado, J.C. Yang, R.M. Sherry, S.L. Topalian, U.S. Kammula, R.E. Royal, et al. 2005. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23:6043-6053. http://dx.doi.org/10.1200/JCO.2005.06.205
2. Baban, B., P.R. Chandler, B.A. Johnson III, L. Huang, M. Li, M.L. Sharpe, L.M. Francisco, A.H. Sharpe, B.R. Blazar, D.H. Munn, and A.L. Mellor. 2011. Physiologic control of IDO competence in splenic dendritic cells. J. Immunol. 187:2329-2335. http://dx.doi.org/10.4049/jimmunol.1100276
3. Balachandran, V.P., M.J. Cavnar, S. Zeng, Z.M. Bamboat, L.M. Ocuin, H. Obaid, E.C. Sorenson, R. Popow, C. Ariyan, F. Rossi, et al. 2011. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat. Med. 17:1094-1100. http://dx.doi.org/10.1038/nm.2438
4. Belladonna, M.L., U. Grohmann, P. Guidetti, C. Volpi, R. Bianchi, M.C. Fioretti, R. Schwarcz, F. Fallarino, and P. Puccetti. 2006. Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J. Immunol. 177:130-137.
5. Belladonna, M.L., C. Orabona, U. Grohmann, and P. Puccetti. 2009. TGFbeta and kynurenines as the key to infectious tolerance. Trends Mol. Med. 15:41-49. http://dx.doi.org/10.1016/j.molmed.2008.11.006
6. Brody, J.R., C.L. Costantino, A.C. Berger, T. Sato, M.P. Lisanti, C.J. Yeo, R.V. Emmons, and A.K. Witkiewicz. 2009. Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle. 8: 1930-1934. http://dx.doi.org/10.4161/cc.8.12.8745
7. Bui, J.D., R. Uppaluri, C.S. Hsieh, and R.D. Schreiber. 2006. Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins. Cancer Res. 66:7301-7309. http://dx.doi.org/10.1158/0008-5472.CAN-06-0556
8. Chambers, C.A., M.S. Kuhns, J.G. Egen, and J.P. Allison. 2001. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19:565-594. http://dx.doi.org/10.1146/annurev.immunol.19.1.565
9. Chen, W., X. Liang, A.J. Peterson, D.H. Munn, and B.R. Blazar. 2008. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J. Immunol. 181:5396-5404.
10. Curran, M.A., and J.P. Allison. 2009. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res. 69:7747-7755. http://dx.doi.org/10.1158/0008-5472.CAN-08-3289
11. Curran, M.A., W. Montalvo, H. Yagita, and J.P. Allison. 2010. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. USA. 107:4275-4280. http://dx.doi.org/10.1073/pnas.0915174107
12. Curran, M.A., M. Kim, W. Montalvo, A. Al-Shamkhani, and J.P. Allison. 2011. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS ONE. 6:e19499. http://dx.doi.org/10.1371/journal.pone.0019499
13. Curti, A., S. Pandolfi, B. Valzasina, M. Aluigi, A. Isidori, E. Ferri, V. Salvestrini, G. Bonanno, S. Rutella, I. Durelli, et al. 2007. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25-into CD25+ T regulatory cells. Blood. 109:2871-2877.
14. Diatta, A., E. Piver, C. Collin, P. Vaudin, and J.C. Pagès. 2005. Semliki Forest virus-derived virus-like particles: characterization of their production and transduction pathways. J. Gen. Virol. 86:3129-3136. http://dx.doi.org/10.1099/vir.0.81103-0
15. Downey, S.G., J.A. Klapper, F.O. Smith, J.C. Yang, R.M. Sherry, R.E. Royal, U.S. Kammula, M.S. Hughes, T.E. Allen, C.L. Levy, et al. 2007. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin. Cancer Res. 13:6681-6688. http://dx.doi.org/10.1158/1078-0432.CCR-07-0187
16. Fallarino, F., U. Grohmann, C. Vacca, R. Bianchi, C. Orabona, A. Spreca, M.C. Fioretti, and P. Puccetti. 2002. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 9:1069-1077. http://dx.doi.org/10.1038/sj.cdd.4401073
17. Fallarino, F., U. Grohmann, S. You, B.C. McGrath, D.R. Cavener, C. Vacca, C. Orabona, R. Bianchi, M.L. Belladonna, C. Volpi, et al. 2006. The combined effects of tryptophan starvation and tryptophan catabolites downregulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 176:6752-6761.
18. Friberg, M., R. Jennings, M. Alsarraj, S. Dessureault, A. Cantor, M. Extermann, A.L. Mellor, D.H. Munn, and S.J. Antonia. 2002. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int. J. Cancer. 101:151-155. http://dx.doi.org/10.1002/ijc.10645
19. Frumento, G., R. Rotondo, M. Tonetti, G. Damonte, U. Benatti, and G.B. Ferrara. 2002. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 196:459-468. http://dx.doi.org/10.1084/jem.20020121
20. Grohmann, U., C. Orabona, F. Fallarino, C. Vacca, F. Calcinaro, A. Falorni, P. Candeloro, M.L. Belladonna, R. Bianchi, M.C. Fioretti, and P. Puccetti. 2002. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3:1097-1101. http://dx.doi.org/10.1038/ni846
21. Gu, T., R.B. Rowswell-Turner, M.O. Kilinc, and N.K. Egilmez. 2010. Central role of IFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunity. Cancer Res. 70:129-138. http://dx.doi.org/10.1158/0008-5472.CAN-09-3170
22. Haley, P.J. 2003. Species differences in the structure and function of the immune system. Toxicology. 188:49-71. http://dx.doi.org/10.1016/S0300-483X(03)00043-X
23. Hamid, O., H. Schmidt, A. Nissan, L. Ridolfi, S. Aamdal, J. Hansson, M. Guida, D.M. Hyams, H. Gómez, L. Bastholt, et al. 2011. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J. Transl. Med. 9:204. http://dx.doi.org/10.1186/1479-5876-9-204
24. Harlin, H., T.V. Kuna, A.C. Peterson, Y. Meng, and T.F. Gajewski. 2006. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol. Immunother. 55:1185-1197. http://dx.doi.org/10.1007/s00262-005-0118-2
25. Hodi, F.S., M.C. Mihm, R.J. Soiffer, F.G. Haluska, M. Butler, M.V. Seiden, T. Davis, R. Henry-Spires, S. MacRae, A. Willman, et al. 2003. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA. 100:4712-4717. http://dx.doi.org/10.1073/pnas.0830997100
26. Hodi, F.S., M. Butler, D.A. Oble, M.V. Seiden, F.G. Haluska, A. Kruse, S. Macrae, M. Nelson, C. Canning, I. Lowy, et al. 2008. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl. Acad. Sci. USA. 105:3005-3010. http://dx.doi.org/10.1073/pnas.0712237105
27. Hodi, F.S., S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, J.B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J.C. Hassel, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:711-723. http://dx.doi.org/10.1056/NEJMoa1003466
28. Hou, D.Y., A.J. Muller, M.D. Sharma, J. DuHadaway, T. Banerjee, M. Johnson, A.L. Mellor, G.C. Prendergast, and D.H. Munn. 2007. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 67: 792-801. http://dx.doi.org/10.1158/0008-5472.CAN-06-2925
29. Hurwitz, A.A., T.F. Yu, D.R. Leach, and J.P. Allison. 1998. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA. 95:10067-10071. http://dx.doi.org/10.1073/pnas.95.17.10067
30. Hwu, P., M.X. Du, R. Lapointe, M. Do, M.W. Taylor, and H.A. Young. 2000. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol. 164:3596-3599.
31. Ji, R.R., S.D. Chasalow, L. Wang, O. Hamid, H. Schmidt, J. Cogswell, S. Alaparthy, D. Berman, M. Jure-Kunkel, N.O. Siemers, et al. 2012. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. 61:1019-1031. http://dx.doi.org/10.1007/s00262-011-1172-6
32. Johnson, T.S., and D.H. Munn. 2012. Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance. Immunol. Invest. 41: 765-797. http://dx.doi.org/10.3109/08820139.2012.689405
33. Johnson, B.A. III, D.J. Kahler, B. Baban, P.R. Chandler, B. Kang, M. Shimoda, P.A. Koni, J. Pihkala, B. Vilagos, M. Busslinger, et al. 2010. B-lymphoid cells with attributes of dendritic cells regulate T cells via indoleamine 2,3-dioxygenase. Proc. Natl. Acad. Sci. USA. 107:10644-10648. http://dx.doi.org/10.1073/pnas.0914347107
34. Krummel, M.F., and J.P. Allison. 1996. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 183:2533-2540. http://dx.doi.org/10.1084/jem.183.6.2533
35. Leach, D.R., M.F. Krummel, and J.P. Allison. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 271:1734-1736. http://dx.doi.org/10.1126/science.271.5256.1734
36. Lee, J.H., H. Torisu-Itakara, A.J. Cochran, A. Kadison, Y. Huynh, D.L. Morton, and R. Essner. 2005. Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin. Cancer Res. 11:107-112.
37. Mansfield, A.S., P.S. Heikkila, A.T. Vaara, K.A. von Smitten, J.M. Vakkila, and M.H. Leidenius. 2009. Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer. 9:231. http://dx.doi.org/10.1186/1471-2407-9-231
38. Mellor, A.L., P. Chandler, B. Baban, A.M. Hansen, B. Marshall, J. Pihkala, H. Waldmann, S. Cobbold, E. Adams, and D.H. Munn. 2004. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int. Immunol. 16:1391-1401. http://dx.doi.org/10.1093/intimm/dxh140
39. Mestas, J., and C.C. Hughes. 2004. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172:2731-2738.
40. Metz, R., S. Rust, J.B. Duhadaway, M.R. Mautino, D.H. Munn, N.N. Vahanian, C.J. Link, and G.C. Prendergast. 2012. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology. 1:1460-1468. http://dx.doi.org/10.4161/onci.21716
41. Muller, A.J., J.B. DuHadaway, P.S. Donover, E. Sutanto-Ward, and G.C. Prendergast. 2005a. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11:312-319. http://dx.doi.org/10.1038/nm1196
42. Muller, A.J., W.P. Malachowski, and G.C. Prendergast. 2005b. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin. Ther. Targets. 9:831-849. http://dx.doi.org/10.1517/14728222.9.4.831
43. Munn, D.H., and A.L. Mellor. 2004. IDO and tolerance to tumors. Trends Mol. Med. 10:15-18. http://dx.doi.org/10.1016/j.molmed.2003.11.003
44. Munn, D.H., and A.L. Mellor. 2007. Indoleamine 2,3-dioxygenase and tumorinduced tolerance. J. Clin. Invest. 117:1147-1154. http://dx.doi.org/10.1172/JCI31178
45. Munn, D.H., M. Zhou, J.T. Attwood, I. Bondarev, S.J. Conway, B. Marshall, C. Brown, and A.L. Mellor. 1998. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 281:1191-1193. http://dx.doi.org/10.1126/science.281.5380.1191
46. Munn, D.H., E. Shafizadeh, J.T. Attwood, I. Bondarev, A. Pashine, and A.L. Mellor. 1999. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189:1363-1372. http://dx.doi.org/10.1084/jem.189.9.1363
47. Munn, D.H., M.D. Sharma, J.R. Lee, K.G. Jhaver, T.S. Johnson, D.B. Keskin, B. Marshall, P. Chandler, S.J. Antonia, R. Burgess, et al. 2002. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science. 297:1867-1870. http://dx.doi.org/10.1126/science.1073514
48. Munn, D.H., M.D. Sharma, D. Hou, B. Baban, J.R. Lee, S.J. Antonia, J.L. Messina, P. Chandler, P.A. Koni, and A.L. Mellor. 2004. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumordraining lymph nodes. J. Clin. Invest. 114:280-290.
49. Munn, D.H., M.D. Sharma, B. Baban, H.P. Harding, Y. Zhang, D. Ron, and A.L. Mellor. 2005. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 22:633-642. http://dx.doi.org/10.1016/j.immuni.2005.03.013
50. Okamoto, A., T. Nikaido, K. Ochiai, S. Takakura, M. Saito, Y. Aoki, N. Ishii, N. Yanaihara, K. Yamada, O. Takikawa, et al. 2005. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin. Cancer Res. 11:6030-6039. http://dx.doi.org/10.1158/1078-0432.CCR-04-2671
51. Orabona, C., P. Puccetti, C. Vacca, S. Bicciato, A. Luchini, F. Fallarino, R. Bianchi, E. Velardi, K. Perruccio, A. Velardi, et al. 2006. Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood. 107: 2846-2854. http://dx.doi.org/10.1182/blood-2005-10-4077
52. Park, M.J., S.Y. Min, K.S. Park, Y.G. Cho, M.L. Cho, Y.O. Jung, H.S. Park, S.H. Chang, S.G. Cho, J.K. Min, et al. 2008. Indoleamine 2,3-dioxygenaseexpressing dendritic cells are involved in the generation of CD4+CD25+ regulatory T cells in Peyer's patches in an orally tolerized, collageninduced arthritis mouse model. Arthritis Res. Ther. 10:R11. http://dx.doi.org/10.1186/ar2361
53. Phan, G.Q., J.C. Yang, R.M. Sherry, P. Hwu, S.L. Topalian, D.J. Schwartzentruber, N.P. Restifo, L.R. Haworth, C.A. Seipp, L.J. Freezer, et al. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyteassociated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA. 100:8372-8377. http://dx.doi.org/10.1073/pnas.1533209100
54. Polak, M.E., N.J. Borthwick, F.G. Gabriel, P. Johnson, B. Higgins, J. Hurren, D. McCormick, M.J. Jager, and I.A. Cree. 2007. Mechanisms of local immunosuppression in cutaneous melanoma. Br. J. Cancer. 96:1879-1887. http://dx.doi.org/10.1038/sj.bjc.6603763
55. Pulaski, B.A., and S. Ostrand-Rosenberg. 2001. Mouse 4T1 breast tumor model. Curr Protoc Immunol Chapter 20:Unit 20 22.
56. Qian, F., J. Liao, J. Villella, R. Edwards, P. Kalinski, S. Lele, P. Shrikant, and K. Odunsi. 2012. Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation. Cancer Immunol. Immunother. 61:2013-2020. http://dx.doi.org/10.1007/s00262-012-1265-x
57. Quezada, S.A., K.S. Peggs, M.A. Curran, and J.P. Allison. 2006. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 116:1935-1945. http://dx.doi.org/10.1172/JCI27745
58. Ribas, A., B. Comin-Anduix, J.S. Economou, T.R. Donahue, P. de la Rocha, L.F. Morris, J. Jalil, V.B. Dissette, I.P. Shintaku, J.A. Glaspy, et al. 2009. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin. Cancer Res. 15:390-399. http://dx.doi.org/10.1158/1078-0432.CCR-08-0783
59. Robert, C., L. Thomas, I. Bondarenko, S. O'Day, J.W. M D, C. Garbe, C. Lebbe, J.F. Baurain, A. Testori, J.J. Grob, et al. 2011. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364:2517-2526. http://dx.doi.org/10.1056/NEJMoa1104621
60. Sanderson, K., R. Scotland, P. Lee, D. Liu, S. Groshen, J. Snively, S. Sian, G. Nichol, T. Davis, T. Keler, et al. 2005. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. 23:741-750. http://dx.doi.org/10.1200/JCO.2005.01.128
61. Sato, E., S.H. Olson, J. Ahn, B. Bundy, H. Nishikawa, F. Qian, A.A. Jungbluth, D. Frosina, S. Gnjatic, C. Ambrosone, et al. 2005. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA. 102:18538-18543. http://dx.doi.org/10.1073/pnas.0509182102
62. Schneider, H., J. Downey, A. Smith, B.H. Zinselmeyer, C. Rush, J.M. Brewer, B. Wei, N. Hogg, P. Garside, and C.E. Rudd. 2006. Reversal of the TCR stop signal by CTLA-4. Science. 313:1972-1975. http://dx.doi.org/10.1126/science.1131078
63. Sharma, M.D., B. Baban, P. Chandler, D.Y. Hou, N. Singh, H. Yagita, M. Azuma, B.R. Blazar, A.L. Mellor, and D.H. Munn. 2007. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest. 117:2570-2582. http://dx.doi.org/10.1172/JCI31911
64. Sharma, M.D., D.Y. Hou, Y. Liu, P.A. Koni, R. Metz, P. Chandler, A.L. Mellor, Y. He, and D.H. Munn. 2009. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood. 113:6102-6111. http://dx.doi.org/10.1182/blood- 2008-12-195354
65. Suzuki, S., S. Toné, O. Takikawa, T. Kubo, I. Kohno, and Y. Minatogawa. 2001. Expression of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase in early concepti. Biochem. J. 355:425-429. http://dx.doi.org/10.1042/0264-6021:3550425
66. Taylor, M.W., and G.S. Feng. 1991. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 5: 2516-2522.
67. Terness, P., T.M. Bauer, L. Röse, C. Dufter, A. Watzlik, H. Simon, and G. Opelz. 2002. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196:447-457. http://dx.doi.org/10.1084/jem.20020052
68. Uyttenhove, C., L. Pilotte, I. Théate, V. Stroobant, D. Colau, N. Parmentier, T. Boon, and B.J. Van den Eynde. 2003. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9:1269-1274. http://dx.doi.org/10.1038/nm934
69. van Elsas, A., A.A. Hurwitz, and J.P. Allison. 1999. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190:355-366. http://dx.doi.org/10.1084/jem.190.3.355
70. Weinlich, G., C. Murr, L. Richardsen, C. Winkler, and D. Fuchs. 2007. Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology (Basel). 214:8-14. http://dx.doi.org/10.1159/000096906
71. Witkiewicz, A., T.K. Williams, J. Cozzitorto, B. Durkan, S.L. Showalter, C.J. Yeo, and J.R. Brody. 2008. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J. Am. Coll. Surg. 206:849-854, discussion :854-856. http://dx.doi.org/10.1016/j.jamcollsurg.2007.12.014
72. Wolchok, J.D., and Y. Saenger. 2008. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist. 13(Suppl 4):2-9. http://dx.doi.org/10.1634/theoncologist.13-S4-2
73. Yu, G., H. Dai, J. Chen, L. Duan, M. Gong, L. Liu, P. Xiong, C.Y. Wang, M. Fang, and F. Gong. 2008. Gene delivery of indoleamine 2,3-dioxygenase prolongs cardiac allograft survival by shaping the types of T-cell responses. J. Gene Med. 10:754-761. http://dx.doi.org/10.1002/jgm.1201
74. Yuasa, H.J., H.J. Ball, C.J. Austin, and N.H. Hunt. 2010. 1-L-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-D-methyltryptophan. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 157: 10-15. http://dx.doi.org/10.1016/j.cbpb.2010.04.006